Ramosetron hydrochloride

Molecular Structure:    
  • Cat. #:    AKA-08
  • Product:    Ramosetron hydrochloride
  • CAS No.:    132907-72-3
  • Molecular Formula:    C17H18ClN3O
  • Molecular Weight:    315.79732 [g/mol]
  • Chemical Name:    (1-methylindol-3-yl)-[(5R)-4,5,6,7-tetrahydro-3H-benzimidazol-5-yl]methanone;hydrochloride
  • Specification:    99%min
  • Packing:    50g/bag; 100g/bag; 500g/bag; 1kg/bag
  • Availability:    In stock
  • OtherName:    Ramosetron hydrochloride, Nasea, 132907-72-3, Ramosetron.HCl
    Product References:    

Our Ramosetron hydrochloride is sold as chemical only, not as licensed API; The buyer is reponsible for all the legal and regulatory issues in your own country.

Aktin is soley responsible for the product quality.

Ramosetron Hcl is a highly selective, long acting 5-HT3 receptor antagonist. It improves abnormal bowel movement associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It also improves visceral hypersensitivity by suppressing the transmission of intestinal nociception.  
  
  INDICATIONS : Treatment of diarrhea-predominant irritable bowel syndrome in male patients. This drug is not administered to women because of a high incidence of side effects reported, although it is found to be effective during the clinical trials.  
  
  CONTRAINDICATIONS : Hypersensitivity.  
  
  SAFETY PROFILE :Should be used only in those mail patients how have failed to respond to conventional therapy. Ramosetron should not be used i patients with constipatiion predominant irritable bowel syndrome. Diseases showing similar symptoms as IBS (e.g.inflammatory bowel syndrome, colon cancer, infectious enteritis) should be excluded prior to initiation of therapy with Ramosetron patients taking treatment of diarrhea.
      
  ADVERSE EFFECTS :Abdominal pain, Hard stools, Constipation, bloating, Hepatic dysfunction, reflux esophagitis, decrease in platelet count, Increase in white blood cell count, Duodenal ulcer, Nausea, Vomiting, Proteinurea, Palpitation.  
  
  DRUG INTERACTIONS : CYP1A2 inhibiting drugs used in conjuction with ramosetron may increase the blood concentration and action of ramosetron due to inhibition of metabolism. Tricyclic antidepressants, Phenothiazine Antipsychotics, Anticholinergics, MAO inhibitors, opioid agents, used in conjunction with ramosetron may enhance development of constipation and other G.I. adverse effects.  
  
  DOSAGE :5mcg OD. Maximum daily dose 10mcg, Before the implementation of dosage adjustment, patients Symptoms should be observed for one month. If frequent changes in symptoms occur, dosage adjustment should not be implemented.
 

 
Inquiry Online Now  or
By email: info@aktinchem.com
By Phone: (86)28-85159085